{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:03:37Z","timestamp":1792191817692,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Ischaemic stroke patients with atrial fibrillation (AF) are at high risk of stroke recurrence despite oral anticoagulation therapy. Patients with cardiovascular comorbidities may take both antiplatelet and oral anticoagulation therapy (OAC\/AP). Our study aims to evaluate the safety and efficacy of OAC\/AP therapy as secondary prevention in people with AF and ischaemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>We performed a post-hoc analysis of pooled individual data from multicenter prospective cohort studies and compared outcomes in the OAC\/AP cohort and patients on DOAC\/VKA anticoagulation alone (OAC cohort). Primary outcome was a composite of ischaemic stroke, systemic embolism, intracranial bleeding, and major extracranial bleeding, while secondary outcomes were ischaemic and haemorrhagic events considered separately. A multivariable logistic regression analysis was performed to identify independent predictors for outcome events. To compare the risk of outcome events between the two cohorts, the relation between the survival function and the set of explanatory variables were calculated by Cox proportional hazard models and the results were reported as adjusted hazard ratios (HR). Finally another analysis was performed to compare the overall risk of outcome events in both OAC\/AP and OAC cohorts after propensity score matching (PSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During a mean follow-up time of 7.5\u2009\u00b1\u20099.1\u2009months (median follow-up time 3.5\u2009months, interquartile range \u00b13), 2284 stroke patients were on oral anticoagulants and 215 were on combined therapy. The multivariable model demonstrated that the composite outcome is associated with age (OR: 1.03, 95% CI: 1.01\u20131.04 for each year increase) and concomitant antiplatelet therapy (OR: 2.2, 95% CI: 1.48\u20133.27), the ischaemic outcome with congestive heart failure (OR: 1.55, 95% CI: 1.02\u20132.36) and concomitant antiplatelet therapy (OR: 1.93, 95% CI: 1.19\u20133.13) and the haemorrhagic outcome with age (OR: 1.03, 95% CI: 1.01\u20131.06 for each year increase), alcoholism (OR: 2.15, 95% CI: 1.06\u20134.39) and concomitant antiplatelet therapy (OR: 2.22, 95% CI: 1.23\u20134.02). Cox regression demonstrated a higher rate of the composite outcome (hazard ratio of 1.93 [95% CI, 1.35\u20132.76]), ischaemic events (HR: 2.05 [95% CI: 1.45\u20132.87]) and bleeding outcomes (HR: 1.90 [95% CI, 1.06\u20133.40]) in OAC\/AP cohort. After PSM analysis, the composite outcome remained more frequent in people treated with OAC\u2009+\u2009AP (RR: 1.70 [95% CI, 1.05\u20132.74]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Secondary prevention with combination of oral anticoagulant and antiplatelet therapy after ischaemic stroke was associated with worse outcomes in our cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Further research is needed to improve secondary prevention by investigating the mechanisms of recurrent ischaemic stroke in patients with atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873231183211","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T05:03:54Z","timestamp":1689570234000},"page":"722-730","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy"],"prefix":"10.1093","volume":"8","author":[{"name":"RAF and RENO-EXTEND Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"2026012113102338100_bibr1-23969873231183211","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"2026012113102338100_bibr2-23969873231183211","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"key":"2026012113102338100_bibr3-23969873231183211","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"2026012113102338100_bibr4-23969873231183211","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"2026012113102338100_bibr5-23969873231183211","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092938","article-title":"Etiology of ischemic strokes of patients with atrial fibrillation and therapy with anticoagulants","volume":"9","author":"Purrucker","year":"2020","journal-title":"J Clin Med"},{"key":"2026012113102338100_bibr6-23969873231183211","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/jnnp-2021-328391","article-title":"Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation","volume":"93","author":"Polymeris","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113102338100_bibr7-23969873231183211","doi-asserted-by":"crossref","first-page":"e034778","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"10","author":"Salmasi","year":"2020","journal-title":"BMJ Open"},{"key":"2026012113102338100_bibr8-23969873231183211","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1161\/STROKEAHA.120.030258","article-title":"Left atrial appendage thrombus detected during hyperacute stroke imaging is associated with atrial fibrillation","volume":"51","author":"Senadeera","year":"2020","journal-title":"Stroke"},{"key":"2026012113102338100_bibr9-23969873231183211","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/jnnp-2020-323963","article-title":"Ischaemic stroke in anticoagulated patients with atrial fibrillation","volume":"92","author":"Stretz","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113102338100_bibr10-23969873231183211","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s11239-020-02108-5","article-title":"The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm","volume":"50","author":"Rota","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113102338100_bibr11-23969873231183211","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2026012113102338100_bibr12-23969873231183211","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113102338100_bibr13-23969873231183211","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaneurol.2019.2984","article-title":"Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS Trial","volume":"77","author":"Perera","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026012113102338100_bibr14-23969873231183211","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS trial","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation"},{"key":"2026012113102338100_bibr15-23969873231183211","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ahj.2006.06.024","article-title":"Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials","volume":"152","author":"Flaker","year":"2006","journal-title":"Am. Heart J"},{"key":"2026012113102338100_bibr16-23969873231183211","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2026012113102338100_bibr17-23969873231183211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11239-016-1425-5","article-title":"Combined aspirin and anticoagulant therapy in patients with atrial fibrillation","volume":"43","author":"So","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113102338100_bibr18-23969873231183211","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1074248420923528","article-title":"The combination of oral anticoagulant and antiplatelet therapies: Stay One Step ahead","volume":"25","author":"Luc\u00e0","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012113102338100_bibr19-23969873231183211","doi-asserted-by":"crossref","first-page":"e007034","DOI":"10.1161\/JAHA.117.007034","article-title":"Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study","volume":"6","author":"Paciaroni","year":"2017","journal-title":"JAHA"},{"key":"2026012113102338100_bibr20-23969873231183211","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","article-title":"Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation","volume":"46","author":"Paciaroni","year":"2015","journal-title":"Stroke"},{"key":"2026012113102338100_bibr21-23969873231183211","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1161\/STROKEAHA.121.038239","article-title":"Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study","volume":"53","author":"Paciaroni","year":"2022","journal-title":"Stroke"},{"key":"2026012113102338100_bibr22-23969873231183211","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026012113102338100_bibr23-23969873231183211","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1747-4949.2009.00271.x","article-title":"Functional outcome measures in contemporary stroke trials","volume":"4","author":"Quinn","year":"2009","journal-title":"Int J Stroke"},{"key":"2026012113102338100_bibr24-23969873231183211","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"2026012113102338100_bibr25-23969873231183211","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.atherosclerosis.2010.06.016","article-title":"Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention","volume":"212","author":"Paciaroni","year":"2010","journal-title":"Atherosclerosis"},{"key":"2026012113102338100_bibr26-23969873231183211","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/STROKEAHA.119.025350","article-title":"Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention","volume":"50","author":"Paciaroni","year":"2019","journal-title":"Stroke"},{"key":"2026012113102338100_bibr27-23969873231183211","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/ene.13280","article-title":"Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk","volume":"24","author":"Lehtola","year":"2017","journal-title":"Eur J Neurol"},{"key":"2026012113102338100_bibr28-23969873231183211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/STROKEAHA.120.029474","article-title":"Small vessel disease and ischemic stroke risk during anticoagulation for atrial fibrillation after cerebral ischemia","volume":"52","author":"Du","year":"2021","journal-title":"Stroke"},{"key":"2026012113102338100_bibr29-23969873231183211","doi-asserted-by":"crossref","first-page":"e200107","DOI":"10.1001\/jamanetworkopen.2020.0107","article-title":"Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation","volume":"3","author":"Fox","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026012113102338100_bibr30-23969873231183211","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"key":"2026012113102338100_bibr31-23969873231183211","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. Warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113102338100_bibr32-23969873231183211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial","volume":"179","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"2026012113102338100_bibr33-23969873231183211","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113102338100_bibr34-23969873231183211","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1161\/CIR.0000000000000568","article-title":"Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association","volume":"137","author":"Chen","year":"2018","journal-title":"Circulation"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873231183211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873231183211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/8\/3\/722\/64646985\/23969873231183211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/8\/3\/722\/64646985\/23969873231183211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:11:33Z","timestamp":1769019093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/8\/3\/722\/8269060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873231183211","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,9,1]]}}}